New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For NDAQ;AAPL;BBRY;HD;GOOG;REGN;SNY;NVO;HEK;GMCR From The Last 14 Days
Check below for free stories on NDAQ;AAPL;BBRY;HD;GOOG;REGN;SNY;NVO;HEK;GMCR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>
July 31, 2014
06:21 EDTAAPLApple said to fire 200 Beats employees after buyout, Bloomberg says
Subscribe for More Information
06:02 EDTGOOGGoogle implied volatility of 18 at lower end of index mean range
Subscribe for More Information
05:56 EDTSNYSanofi reports Q2 business net income up 13% to EUR 1.54B
Subscribe for More Information
July 30, 2014
16:31 EDTSNY, REGNRegeneron, Sanofi announce plan to use priority review voucher for alirocumab
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the companies intend to use a FDA rare pediatric disease priority review voucher in connection with the Biologics License Application, or BLA, submission for alirocumab. The priority review voucher entitles the holder to designate a BLA for priority review, which provides for an expedited 6-month review from the filing date instead of the standard 10-month review. Regeneron Ireland, an indirect, wholly-owned subsidiary of Regeneron Pharmaceuticals, purchased the voucher from BioMarin GALNS, a direct, wholly-owned subsidiary of BioMarin Pharmaceutical (BMRN), which had received it through the FDA's rare pediatric disease priority review voucher program. Sanofi and Regeneron will equally share the purchase price of $67.5M. Sanofi and Regeneron expect to submit U.S. and EU regulatory submissions for alirocumab before year end.
16:24 EDTREGNBioMarin sells priority review voucher for $67.5M to Regeneron
BioMarin Pharmaceutical (BMRN) announced that it has sold the Rare Pediatric Disease Priority Review Voucher it obtained in February of this year. The company received the voucher under an FDA program intended to encourage the development of treatments for rare pediatric diseases. BioMarin was awarded the voucher when it received approval of VIMIZIM, a new biological product for patients with Mucopolysaccharidosis type IVA, also known as Morquio A syndrome. BioMarin received $67.5M from Regeneron Ireland, an indirect, wholly-owned subsidiary of Regeneron Pharmaceuticals (REGN), in exchange for the voucher. "Leveraging the sale of the Priority Review Voucher to reinvest in products to treat rare and ultra-rare diseases makes the most sense for BioMarin given our stage of growth," said Jean-Jacques Bienaimé, CEO of BioMarin.
16:00 EDTAAPLOptions Update; July 30, 2014
Subscribe for More Information
14:30 EDTAAPLApple tells engineers not to expect TV launch this year, The Information says
Apple (AAPL) engineers working on the company's television product have been told not to expect a launch this year, with the tech giant citing cable companies “dragging their heals” and the pending merger of Comcast (CMCSA) and Time Warner Cable (TWC) as reasons the TV service has been delayed, according to The Information, citing a person familiar with the company's plans. Reference Link
12:33 EDTSNY, REGNRegeneron, Sanofi likely to file alirocumab BLA this year, says Piper Jaffray
Subscribe for More Information
12:27 EDTREGNOn The Fly: Midday Wrap
Subscribe for More Information
11:57 EDTAAPL, BBRY, GOOGNew COO Beard says BlackBerry will 'prove' people incorrect, WSJ says
Even though BlackBerry (BBRY) is up against obstacles from rivals such as Apple (AAPL) and Google's (GOOG) Android smartphones, the company's new COO Marty Beard says that the firm is positioned to "prove people wrong" and take advantage of an emerging market for internet-connected devices, according to The Wall Street Journal, citing comments from Beard. Reference Link
09:53 EDTAAPLBest Buy CEO Joly says sales of tablets 'crashing,' Re/code reports
Subscribe for More Information
09:38 EDTAAPLActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL AMZN TWTR NFLX GILD C MA FB RFMD AMGN GNW TSLA
08:31 EDTAAPLInvenSense likely obtained substantial business from Apple, says Pacific Crest
Subscribe for More Information
08:23 EDTNDAQSEC may consider rule change, allowing IEX to be exchange, Reuters says
IEX Group, which was described in Michael Lewis' book "Flash Boys" as a place for investors to place buy and sell orders without worrying that they are being "front-run" by high-speed traders, may be aided in its goal of becoming a full-fledged stock exchange as the SEC may revisit rules that require the fastest possible execution of securities trades, said Reuters, citing a person familiar with the SEC's thinking. Publicly traded stock exchange owners include NASDAQ (NDAQ), IntercontinentalExchange (ICE) and BATS Global Markets (BATS). Reference Link
08:15 EDTAAPLApple's iPad global market share may ship below 25% in 2H14, DigiTimes says
Subscribe for More Information
08:08 EDTSNY, REGNSanofi and Regeneron report positive Phase 2 results of alirocumab
Subscribe for More Information
July 29, 2014
19:55 EDTGOOGBaidu developing 'self-driving' car, China Daily reports
Subscribe for More Information
18:38 EDTREGNRegeneron receives FDA approval for EYLEA for treatment of DME
Regeneron Pharmaceuticals announced that the FDA has approved EYLEA Injection for the treatment of Diabetic Macular Edema, or DME. The approval of EYLEA in DME was based on the one-year data from the phase 3 VISTA-DME and VIVID-DME studies of 862 patients. In Europe, the Committee for Medicinal Products for Human Use has given a positive opinion recommending approval for EYLEA in the treatment of DME. Regulatory submissions have also been made in Japan, Asia Pacific, and Latin America for the treatment of DME. In Japan, EYLEA has been additionally submitted for approval to regulators for the treatment of choroidal neovascularization secondary to pathologic myopia. A regulatory submission has been made in the U.S. and Europe for EYLEA for the treatment of Macular Edema following Branch Retinal Vein Occlusion.
16:01 EDTAAPLOptions Update; July 29, 2014
Subscribe for More Information
12:39 EDTAAPL, BBRYFord replacing employees' BlackBerry phones with iPhones, Bloomberg reports
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use